Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 2/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL11786925 | 0.98 | ACP1 (0.60) | ACP1GPR35TAS2R14TMPRSS4P2RX4 | |
| SCHEMBL5833345 | 0.87 | GPR35 (0.66) | ACP1GPR35TMPRSS4P2RX4P2RX7 | |
| SCHEMBL11786916 | 0.86 | ACP1 (0.61) | ACP1GPR35TAS2R14TMPRSS4P2RX4 | |
| Fluoride SCHEMBL11788456 | 0.85 | GPR35 (0.63) | ACP1GPR35TMPRSS4P2RX4P2RX7 | |
| SCHEMBL449135 | 0.84 | ACP1 (0.60) | ACP1GPR35TAS2R14TMPRSS4P2RX4 | |
| SCHEMBL5448110 | 0.84 | ACP1 (0.60) | ACP1GPR35TAS2R14TMPRSS4P2RX4 | |
| SCHEMBL25369424 | 0.82 | ACP1 (0.45) | ACP1GPR35TAS2R14TMPRSS4P2RX4 | |
| SCHEMBL16829544 | 0.82 | MAPK14 (0.46) | ACP1GPR35TAS2R14TMPRSS4P2RX4 | |
| SCHEMBL12513693 | 0.81 | MAPT (0.78) | ACP1GPR35TAS2R14TMPRSS4P2RX4 | |
| SCHEMBL15397572 | 0.80 | ACP1 (0.52) | ACP1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368889-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2011-09-08 | — | — | US | disclosed |
| EP-2357182-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7956053-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2011-06-07 | — | — | US | disclosed |
| US-20090286821-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2009-11-19 | — | — | US | disclosed |
| EP-2100891-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7569566-B2 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| EP-1532138-B1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2008-11-19 | — | — | EP | disclosed |
| CN-101291917-A | Diaryl urea derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2008-08-07 | — | — | US | disclosed |
| CN-101045727-A | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-10-03 | — | — | CN | disclosed |
| CN-1324022-C | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2007-07-04 | — | — | CN | disclosed |
| US-20070093506-A1 | Inhibitors of tyrosine kinases | BREITENSTEIN WERNER | 2007-04-26 | — | — | US | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| CN-1675195-A | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-09-28 | — | — | CN | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093506-A1 | Inhibitors of tyrosine kinases | ABL1, BTK, FLT3 | ACP1 187/4885GPR35 2460/4885TAS2R14 4370/4885 |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ACP1 187/4885GPR35 2460/4885TAS2R14 4370/4885 |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ACP1 187/4885GPR35 2460/4885TAS2R14 4370/4885 |
| US-20090286821-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ACP1 187/4885GPR35 2460/4885TAS2R14 4370/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | ACP1 302/4885GPR35 2735/4885TAS2R14 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.